Supported Research

Clinical trial to investigate the safety and efficacy of Afatinib when administered as therapy in FA patients

2023 | Santa Creu and Sant Pau Hospital Research Institute and Research | Clinical Trial

Amount Funded: $324,733

Individuals with FA have a higher risk of developing head and neck squamous cell carcinoma (HSNCC) at young ages. Long-term survival rates remain low because often these patients cannot tolerate conventional chemotherapy and radiation treatments due to issues related to toxicity. This study is the first clinical trial focused on a therapy for FA-related HNSCC. It will investigate the efficacy and safety of the drug, Afatinib, when administered to people with FA who are diagnosed with unresectable and/or advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.

Researchers: Jordi Surralles, Ramon Garcia Escudero